ACADIA Pharmaceuticals Inc. vs Lockheed Martin Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Lockheed Martin Corporation trades at $597.2 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 27.2× ACADIA Pharmaceuticals Inc.'s market cap, and Lockheed Martin Corporation pays a 2.31% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LMT | |
|---|---|---|
Market Cap | $5.07B | $137.96B |
Sector | Health | Industrials |
52-Week High | $29.41 | $676.70 |
52-Week Low | $20.06 | $431.56 |
Enterprise Value | $4.19B | $154.71B |
Dividend Yield | — | 2.31% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →